Satellos drug forazapadin in 2 Phase 2 DMD trials
Satellos Bioscience secures the INN name forazapadin for SAT-3247 and highlights advancing Phase 2 programs in Duchenne and planned expansion into FSHD.
Rhea-AI Filing Summary
Satellos Bioscience Inc. (MSLE) reports that the World Health Organization has assigned the International Nonproprietary Name “forazapadin” to its lead orally administered small molecule drug candidate previously known as SAT-3247, which is designed to restore muscle regeneration in degenerative muscle diseases.
Forazapadin, an AAK1-targeting candidate, is being evaluated in two Phase 2 studies in Duchenne muscular dystrophy, including BASECAMP in pediatric participants and TRAILHEAD in adults, and Satellos plans a Phase 2 trial in facioscapulohumeral muscular dystrophy by the end of 2026. The company cites significant momentum in its Duchenne programs, with expected BASECAMP enrollment completion this quarter and clinical data in the fourth quarter, and states that its current cash, cash equivalents and short-term investments are expected to fund operations through 2027.
Positive
- None.
Negative
- None.
Key Figures
Phase 2 DMD trials: 2 Phase 2 clinical trials
FSHD Phase 2 timing: by the end of 2026
Cash runway: through 2027
+2 more
5 metrics
Phase 2 DMD trials
2 Phase 2 clinical trials
Forazapadin is being evaluated in two Phase 2 studies in Duchenne muscular dystrophy
FSHD Phase 2 timing
by the end of 2026
Planned start of a Phase 2 clinical trial of forazapadin in facioscapulohumeral muscular dystrophy
Cash runway
through 2027
Company’s stated expectation that current cash, cash equivalents and short-term investments will fund operations
BASECAMP enrollment milestone
this quarter
Expected completion of enrollment in the BASECAMP pediatric Phase 2 DMD study
BASECAMP data timing
fourth quarter
Expected timing for release of clinical data from the BASECAMP study
Key Terms
International Nonproprietary Name, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, AAK1, +2 more
6 terms
International Nonproprietary Name regulatory
"announced the assignment of the International Nonproprietary Name (INN) “forazapadin”"
International nonproprietary name (INN) is the official generic name assigned to an active pharmaceutical substance that is recognized worldwide and distinct from company brand names. Investors care because an INN creates a common label for comparing products, tracking regulatory approvals, and measuring market demand and competition—like a universal model number that prevents confusion between different brands and helps assess commercial prospects.
Duchenne muscular dystrophy medical
"commercialization in Duchenne muscular dystrophy"
A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.
facioscapulohumeral muscular dystrophy medical
"begin a Phase 2 clinical trial in facioscapulohumeral muscular dystrophy (FSHD)"
A genetic progressive muscle disorder that slowly weakens the face, shoulder blades and upper arms, often making everyday actions like smiling, lifting objects or raising the arms harder over time. Investors care because it represents a clear unmet medical need: treatments or tests that slow progression, restore function, or improve diagnosis can command significant demand and regulatory attention, similar to developing a new fix for a widespread, uncontrolled mechanical fault in a critical system.
AAK1 medical
"Forazapadin targets AAK1, a key protein identified by Satellos"
AAK1 is a human gene that makes a protein acting like a traffic controller inside cells, helping move and sort molecules into and out of the cell. Investors care because drugs that block or modify AAK1 can change how cells handle infections or neurological signals, so evidence that a therapy affects AAK1 can influence the value of biotech pipelines, clinical trial prospects, and future regulatory or commercial outcomes.
Phase 2 clinical trial medical
"intends to begin a Phase 2 clinical trial in facioscapulohumeral"
A phase 2 clinical trial is a research study that tests a new medical treatment or drug to see if it is effective and safe for a specific condition. It involves a larger group of people than earlier trials and helps determine whether the treatment should move forward to more extensive testing. For investors, successful phase 2 results can signal potential for future approval and commercial success, while setbacks may indicate challenges ahead.
disease-modifying treatment medical
"being evaluated as a potential disease-modifying treatment, for DMD"
A disease-modifying treatment is a therapy that changes the underlying course of a chronic illness rather than only easing symptoms, like repairing a leak in a roof instead of just mopping up the water. For investors it matters because such treatments can sustain patient benefits over time, command higher prices, shift long-term healthcare costs and create lasting market advantages or risks depending on how widely and quickly they are adopted and reimbursed.
FAQ
What key update did Satellos Bioscience (MSLE) announce about SAT-3247 on this Form 6-K?
Satellos announced that its lead drug candidate SAT-3247 has been assigned the International Nonproprietary Name “forazapadin” through the World Health Organization naming process, providing a globally recognized nonproprietary name as the therapy advances in clinical development.
What is forazapadin and what diseases is Satellos (MSLE) targeting?
Forazapadin is a proprietary, oral, small molecule AAK1 inhibitor designed to restore skeletal muscle repair and regeneration. Satellos is developing it primarily for Duchenne muscular dystrophy (DMD) and plans development in facioscapulohumeral muscular dystrophy (FSHD) and other degenerative muscle conditions.
What clinical trials are underway for forazapadin according to Satellos’ 6-K?
Forazapadin is being evaluated in two Phase 2 DMD trials: BASECAMP, a global, randomized, placebo-controlled study in pediatric participants, and TRAILHEAD, an open-label study in adults living with Duchenne muscular dystrophy.
What upcoming milestones did Satellos (MSLE) highlight for its BASECAMP study?
Satellos stated it expects completion of enrollment in BASECAMP this quarter and the release of clinical data in the fourth quarter, indicating near-term clinical readouts in its pediatric Duchenne muscular dystrophy program.
When does Satellos expect to start a Phase 2 trial of forazapadin in FSHD?
Satellos stated that it intends to begin a Phase 2 clinical trial of forazapadin in facioscapulohumeral muscular dystrophy (FSHD) by the end of 2026, subject to the planned regulatory processes.
How long does Satellos (MSLE) expect its current cash resources to last?
Satellos stated that it expects its current cash, cash equivalents and short-term investments to provide a runway through 2027, based on management’s assumptions and subject to the risks and uncertainties described in its risk factor disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
